409 related articles for article (PubMed ID: 9819224)
21. Inhibition of topoisomerase II catalytic activity by two ruthenium compounds: a ligand-dependent mode of action.
Gopal YN; Jayaraju D; Kondapi AK
Biochemistry; 1999 Apr; 38(14):4382-8. PubMed ID: 10194357
[TBL] [Abstract][Full Text] [Related]
22. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
Sorensen M; Sehested M; Jensen PB
Mol Pharmacol; 1999 Mar; 55(3):424-31. PubMed ID: 10051525
[TBL] [Abstract][Full Text] [Related]
23. Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex.
Constantinou AI; Husband A
Anticancer Res; 2002; 22(5):2581-5. PubMed ID: 12529967
[TBL] [Abstract][Full Text] [Related]
24. Fluorometric assays for DNA topoisomerases and topoisomerase-targeted drugs: quantitation of catalytic activity and DNA cleavage.
Andrea JE; Adachi K; Morgan AR
Mol Pharmacol; 1991 Oct; 40(4):495-501. PubMed ID: 1656189
[TBL] [Abstract][Full Text] [Related]
25. Topoisomerase II-mediated DNA cleavage activity and irreversibility of cleavable complex formation induced by DNA intercalator with alkylating capability.
Kong XB; Rubin L; Chen LI; Ciszewska G; Watanabe KA; Tong WP; Sirotnak FM; Chou TC
Mol Pharmacol; 1992 Feb; 41(2):237-44. PubMed ID: 1311406
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of topoisomerase I function by coralyne and 5,6-dihydrocoralyne.
Wang LK; Rogers BD; Hecht SM
Chem Res Toxicol; 1996; 9(1):75-83. PubMed ID: 8924619
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.
Tanabe K; Ikegami Y; Ishida R; Andoh T
Cancer Res; 1991 Sep; 51(18):4903-8. PubMed ID: 1654204
[TBL] [Abstract][Full Text] [Related]
28. Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinylamino)methane-sulfon-m-anisidide.
DeVore RF; Corbett AH; Osheroff N
Cancer Res; 1992 Apr; 52(8):2156-61. PubMed ID: 1313738
[TBL] [Abstract][Full Text] [Related]
29. Spontaneous DNA lesions poison human topoisomerase IIalpha and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints.
Kingma PS; Greider CA; Osheroff N
Biochemistry; 1997 May; 36(20):5934-9. PubMed ID: 9166762
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II.
Markovits J; Linassier C; Fossé P; Couprie J; Pierre J; Jacquemin-Sablon A; Saucier JM; Le Pecq JB; Larsen AK
Cancer Res; 1989 Sep; 49(18):5111-7. PubMed ID: 2548712
[TBL] [Abstract][Full Text] [Related]
31. Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis.
Hammonds TR; Foster SR; Maxwell A
J Mol Biol; 2000 Jul; 300(3):481-91. PubMed ID: 10884345
[TBL] [Abstract][Full Text] [Related]
32. Use of catalytic topoisomerase II inhibitors to probe mechanisms of chemical-induced clastogenicity in Chinese hamster V79 cells.
Snyder RD
Environ Mol Mutagen; 2000; 35(1):13-21. PubMed ID: 10692223
[TBL] [Abstract][Full Text] [Related]
33. DNA topoisomerase II as the primary target of anti-tumor anthracyclines.
Zunino F; Capranico G
Anticancer Drug Des; 1990 Nov; 5(4):307-17. PubMed ID: 1963303
[TBL] [Abstract][Full Text] [Related]
34. Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine.
Cline SD; Macdonald TL; Osheroff N
Biochemistry; 1997 Oct; 36(42):13095-101. PubMed ID: 9335572
[TBL] [Abstract][Full Text] [Related]
35. Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors.
Jensen LH; Thougaard AV; Grauslund M; Søkilde B; Carstensen EV; Dvinge HK; Scudiero DA; Jensen PB; Shoemaker RH; Sehested M
Cancer Res; 2005 Aug; 65(16):7470-7. PubMed ID: 16103101
[TBL] [Abstract][Full Text] [Related]
36. Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded DNA cleavage.
Bromberg KD; Burgin AB; Osheroff N
Biochemistry; 2003 Apr; 42(12):3393-8. PubMed ID: 12653542
[TBL] [Abstract][Full Text] [Related]
37. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
38. Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26.
Catapano CV; Carbone GM; Pisani F; Qiu J; Fernandes DJ
Biochemistry; 1997 May; 36(19):5739-48. PubMed ID: 9153414
[TBL] [Abstract][Full Text] [Related]
39. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
40. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.
Onda T; Toyoda E; Miyazaki O; Seno C; Kagaya S; Okamoto K; Nishikawa K
Cancer Lett; 2008 Jan; 259(1):99-110. PubMed ID: 17998154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]